Molsoft — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 1999 and headquartered in San Diego, Molsoft is a private, revenue-generating company operating as a software platform and services provider. Its core offering is the ICM (Internal Coordinate Mechanics) software suite, which integrates physics-based simulation, flexible docking, virtual screening, and AI models for pharmacology prediction. Molsoft serves a global customer base in life sciences R&D, enabling target assessment, lead discovery, and optimization through its proprietary computational technologies and expert consulting.

AI / Machine LearningDrug DeliveryProteomics

Technology Platform

The ICM (Internal Coordinate Mechanics) software suite, integrating physics-based molecular modeling (Biased Probability Monte Carlo, Molecular Dynamics), flexible docking, virtual screening, homology modeling, cheminformatics tools, and AI/ML models (MolScreen) for pharmacology and toxicology prediction.

Opportunities

The growing reliance on computational methods in drug discovery creates a sustained demand for advanced, integrated platforms like ICM.

Expanding its AI/ML model library (MolScreen) and offering cloud-based virtual screening present significant upsell and market expansion opportunities.

Forming strategic partnerships with pharmaceutical companies for embedded use of its technology or co-development projects could drive substantial service and licensing revenue.

Risk Factors

Intense competition from both large commercial software vendors and free academic tools pressures market share and pricing.

Technological obsolescence is a constant risk if the company fails to keep pace with rapid advances in AI and computing.

As a likely small private firm, resource limitations may hinder sales, marketing, and R&D scale compared to larger, well-funded competitors.

Competitive Landscape

Molsoft competes in the molecular modeling and drug discovery software market against large public companies like Schrödinger and the BIOVIA suite from Dassault Systèmes, as well as other specialized providers. It also faces competition from widely used academic and open-source tools. Its differentiation lies in the integrated ICM platform combining robust physics-based methods with emerging AI, and its deep expertise in consulting services.

More companies in AI / Machine Learning →More companies in United States →